local_hospital

Azienda Ulss 3 Serenissima

Address
lock Available on a paid plan

Cardiovascular Diseases and Thromboembolic Care

At Azienda Ulss 3 Serenissima, research in cardiovascular diseases focuses on conditions such as atrial fibrillation, broader cardiovascular disease, and prevention of venous thromboembolism. These studies aim to improve rhythm control, reduce recurrence of blood clots, and evaluate new options for better long-term heart and vessel health.

  • atrial fibrillation and rhythm management
  • venous thromboembolism recurrence prevention
  • new therapies for cardiovascular risk reduction

The site is also involved in studies of metabolic and cardiovascular risk, reflecting a broad effort to test treatments that may improve everyday clinical outcomes.

Hematology, Lymphoma, and Leukemia Research

A major part of the trial portfolio at this Venice hospital site centers on hemic and lymphatic diseases, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma. The research is designed to test new targeted and combination approaches, while also improving outcomes after transplant and in difficult-to-treat blood cancers.

  • targeted treatment for lymphoma subtypes
  • new strategies for leukemia and transplant-related care
  • improving disease control in relapsed or high-risk blood cancers

This area includes work on multiple myeloma, graft-versus-host disease, and other complex hematologic conditions where better response and durability of treatment are key goals.

Oncology Across Solid Tumors

Clinical trials in neoplasms at Azienda Ulss 3 Serenissima cover a wide range of cancers, including non-small cell lung cancer, ovarian cancer, endometrial cancer, breast cancer, colorectal cancer, and head and neck cancer. The main purpose is to assess new treatments, compare treatment options, and improve outcomes in both newly diagnosed and recurrent disease.

  • testing new therapies for lung cancer and ovarian cancer
  • treatment comparisons in breast, endometrial, and colorectal cancer
  • studies in head and neck and other solid tumors

The oncology program emphasizes whether newer approaches can extend survival, delay recurrence, or improve disease control for patients with advanced or high-risk cancers.

Women’s Health and Hormonal Disorders

Research in female urogenital diseases and pregnancy complications and hormonal diseases includes studies in endometrial cancer, ovarian cancer, and treatment-related vasomotor symptoms in women with breast cancer. These trials aim to improve symptom control, support quality of life, and evaluate better treatment approaches for hormone-related conditions.

  • symptom relief for vasomotor symptoms
  • treatment research in endometrial and ovarian cancer
  • improving care for hormone-related health problems

The site’s research in this area links cancer care with broader women’s health needs, especially where hormonal changes affect daily life and treatment choices.

Immune System, Metabolic, and Supportive Care Studies

Additional trials at this hospital/clinic explore immune system diseases, nutritional and metabolic diseases, and other pathological conditions. This includes research in chronic graft-versus-host disease, prevention of major cardiovascular events, and supportive approaches that may make cancer treatment easier to tolerate.

  • immune-related complications such as graft-versus-host disease
  • metabolic and cardiovascular prevention research
  • supportive care to improve treatment experience

Overall, the research portfolio combines disease-focused studies with efforts to improve safety, quality of life, and long-term patient outcomes across several specialties.

Site Overview

assignment
33
connected trials
corporate_fare
34
sponsors
science
78
IMPs

Activity Indicator

Last 6 months

1
Trials started
-50% vs previous period.
2
Trials started 6–12 months ago
33
Total trials linked
Highly Active
trending_downDeclining-50%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 8 therapeutic areas and 15 of 78 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 72 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
13
Sponsors (total)
34
Active sponsors
13

Sponsor Network

Top 13 by active trials.

lock +12 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +2 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
33
Outperforms 80% of sites
public
Therapeutic diversity
8areas
Outperforms 81% of sites
groups
Sponsor diversity
34sponsors
Outperforms 84% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda Ulss 3 Serenissima

lock Showing 1 of 33 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 78 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Bevacizumab5Unknown2015-11-232024-12-01

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.